Milestone Pharmaceuticals (MIST) has released an update.
Milestone Pharmaceuticals has announced the FDA’s acceptance of their NDA for CARDAMYST, a new nasal spray for PSVT, with a PDUFA date set for March 2025, and reported a strong cash position to fund operations into 2026. Additionally, the company is progressing with a Phase 3 trial for etripamil in AFib-RVR, aiming to start in the first half of 2025.
For further insights into MIST stock, check out TipRanks’ Stock Analysis page.
